标题
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-01-09
DOI
10.1186/s40425-018-0495-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines
- (2018) Stephen J. Russell et al. CANCER CELL
- Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis
- (2018) Ulrich M. Lauer et al. CLINICAL CANCER RESEARCH
- Cancer vaccines: translation from mice to human clinical trials
- (2018) Hoyoung Maeng et al. CURRENT OPINION IN IMMUNOLOGY
- Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses
- (2018) Erkko Ylösmäki et al. MOLECULAR THERAPY
- Superagonist IL-15-armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
- (2018) Stacy J. Kowalsky et al. MOLECULAR THERAPY
- Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer
- (2018) Audrey H. Choi et al. SURGERY
- Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
- (2018) Shashi Gujar et al. OncoImmunology
- Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus
- (2018) Hannah M. Burgess et al. Molecular Therapy-Oncolytics
- Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways
- (2018) Ernesto Mejías-Pérez et al. Molecular Therapy-Oncolytics
- A Novel Oncolytic Chimeric Orthopoxvirus Encoding Luciferase Enables Real-Time View of Colorectal Cancer Cell Infection
- (2018) Michael P. O’Leary et al. Molecular Therapy-Oncolytics
- Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency
- (2018) Marine Ricordel et al. Cancers
- Immunogenic cell death of dendritic cells following modified vaccinia virus Ankara infection enhances CD8+ T cell proliferation
- (2018) Kim A. Tappe et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice
- (2018) Flavia Chiuppesi et al. JOURNAL OF VIROLOGY
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- White paper on microbial anti-cancer therapy and prevention
- (2018) Neil S. Forbes et al. Journal for ImmunoTherapy of Cancer
- The 2018 Nobel Prize in medicine goes to cancer immunotherapy
- (2018) Zong Sheng Guo BMC CANCER
- Noncoding regions are the main source of targetable tumor-specific antigens
- (2018) Céline M. Laumont et al. Science Translational Medicine
- Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2
- (2018) Zuqiang Liu et al. Nature Communications
- Vaccinia virus evasion of regulated cell death
- (2017) David L. Veyer et al. IMMUNOLOGY LETTERS
- Vaccinia virus protein A49 activates Wnt signalling by targetting the E3 ligase β-TrCP
- (2017) Carlos Maluquer de Motes et al. JOURNAL OF GENERAL VIROLOGY
- Vaccinia Virus Encodes a Novel Inhibitor of Apoptosis That Associates with the Apoptosome
- (2017) Melissa R. Ryerson et al. JOURNAL OF VIROLOGY
- Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response
- (2017) Mauro Di Pilato et al. JOURNAL OF VIROLOGY
- Deletion of the K1L Gene Results in a Vaccinia Virus That Is Less Pathogenic Due to Muted Innate Immune Responses, yet Still Elicits Protective Immunity
- (2017) Ariana G. Bravo Cruz et al. JOURNAL OF VIROLOGY
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Inhibition of DAI-dependent necroptosis by the Z-DNA binding domain of the vaccinia virus innate immune evasion protein, E3
- (2017) Heather Koehler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors
- (2017) Emmanuelle Schaedler et al. VACCINE
- Poxviruses Utilize Multiple Strategies to Inhibit Apoptosis
- (2017) et al. Viruses-Basel
- Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
- (2017) Zuqiang Liu et al. Nature Communications
- Cytoplasmic ATR Activation Promotes Vaccinia Virus Genome Replication
- (2017) Antonio Postigo et al. Cell Reports
- Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
- (2017) Christelle Remy-Ziller et al. Human Vaccines & Immunotherapeutics
- Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives
- (2017) Zong Sheng Guo et al. Frontiers in Immunology
- The vaccinia virus K7 protein promotes histone methylation associated with heterochromatin formation
- (2017) Wondimagegnehu M. Teferi et al. PLoS One
- Coinhibitory Pathways in Immunotherapy for Cancer
- (2016) Susanne H. Baumeister et al. Annual Review of Immunology
- Oncolytic vaccine virus harbouring the IL-24 gene suppresses the growth of lung cancer by inducing apoptosis
- (2016) Chunwei Lv et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Cancer immunotherapy: the beginning of the end of cancer?
- (2016) Sofia Farkona et al. BMC Medicine
- Oncolytic viruses: finally delivering
- (2016) Leonard W Seymour et al. BRITISH JOURNAL OF CANCER
- Oncolytic Virus-Mediated Targeting of PGE 2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy
- (2016) Weizhou Hou et al. CANCER CELL
- Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells
- (2016) Susan P. Foy et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9
- (2016) Lili Deng et al. CANCER LETTERS
- TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
- (2016) Elisabeth Quoix et al. LANCET ONCOLOGY
- Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers
- (2016) Stephanie Downs-Canner et al. MOLECULAR THERAPY
- Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
- (2016) Antonio Marchini et al. Viruses-Basel
- Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses
- (2016) María Holgado et al. Viruses-Basel
- Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer
- (2016) Lily Francis et al. Oncotarget
- Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis
- (2016) Michelle J. Wilkinson et al. Oncotarget
- Vaccinia Virus Protein C6 Inhibits Type I IFN Signalling in the Nucleus and Binds to the Transactivation Domain of STAT2
- (2016) Jennifer H. Stuart et al. PLoS Pathogens
- VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection
- (2015) Rozanne Arulanandam et al. CANCER CELL
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Therapeutic cancer vaccines
- (2015) Cornelis J.M. Melief et al. JOURNAL OF CLINICAL INVESTIGATION
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer
- (2015) Se Hoon Park et al. MOLECULAR THERAPY
- First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity
- (2015) Herbert J Zeh et al. MOLECULAR THERAPY
- NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses
- (2015) Mauro Di Pilato et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy
- (2015) Zuqiang Liu et al. OncoImmunology
- Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
- (2015) Annie A Wu et al. OncoImmunology
- Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer
- (2015) Christopher R. Heery et al. JAMA Oncology
- Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land
- (2014) Z S Guo et al. CANCER GENE THERAPY
- A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer
- (2014) L. S. Chard et al. CLINICAL CANCER RESEARCH
- A novel multi-epitope peptide vaccine against cancer: An in silico approach
- (2014) Navid Nezafat et al. JOURNAL OF THEORETICAL BIOLOGY
- Modified Vaccinia Virus Ankara Triggers Type I IFN Production in Murine Conventional Dendritic Cells via a cGAS/STING-Mediated Cytosolic DNA-Sensing Pathway
- (2014) Peihong Dai et al. PLoS Pathogens
- Consensus guidelines for the detection of immunogenic cell death
- (2014) Oliver Kepp et al. OncoImmunology
- Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
- (2013) C. J. Breitbach et al. CANCER RESEARCH
- Vaccinia Virus F11 Promotes Viral Spread by Acting as a PDZ-Containing Scaffolding Protein to Bind Myosin-9A and Inhibit RhoA Signaling
- (2013) Yutaka Handa et al. Cell Host & Microbe
- Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infection
- (2013) C. T. O. Benfield et al. JOURNAL OF GENERAL VIROLOGY
- Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity
- (2013) G. L. Smith et al. JOURNAL OF GENERAL VIROLOGY
- Oncolytic viruses as therapeutic cancer vaccines
- (2013) David L Bartlett et al. Molecular Cancer
- A Rationally Designed A34R Mutant Oncolytic Poxvirus: Improved Efficacy in Peritoneal Carcinomatosis
- (2013) Pragatheeshwar Thirunavukarasu et al. MOLECULAR THERAPY
- Vaccinia Virus Induces Programmed Necrosis in Ovarian Cancer Cells
- (2013) Lynsey M Whilding et al. MOLECULAR THERAPY
- T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy
- (2013) Feng Yu et al. MOLECULAR THERAPY
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
- (2013) Jeong Heo et al. NATURE MEDICINE
- Vaccinia virus F1L protein promotes virulence by inhibiting inflammasome activation
- (2013) M. Gerlic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy
- (2013) Christel Devaud et al. OncoImmunology
- Oncolytic Virus and Anti-4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer
- (2012) L. B. John et al. CANCER RESEARCH
- NF- B Hyperactivation in Tumor Tissues Allows Tumor-Selective Reprogramming of the Chemokine Microenvironment to Enhance the Recruitment of Cytolytic T Effector Cells
- (2012) R. Muthuswamy et al. CANCER RESEARCH
- Protein B5 is required on extracellular enveloped vaccinia virus for repulsion of superinfecting virions
- (2012) V. Doceul et al. JOURNAL OF GENERAL VIROLOGY
- Therapeutic Cancer Vaccines: Current Status and Moving Forward
- (2012) J. Schlom JNCI-Journal of the National Cancer Institute
- Analysis of Viral Membranes Formed in Cells Infected by a Vaccinia Virus L2-Deletion Mutant Suggests Their Origin from the Endoplasmic Reticulum
- (2012) Liliana Maruri-Avidal et al. JOURNAL OF VIROLOGY
- C7L Family of Poxvirus Host Range Genes Inhibits Antiviral Activities Induced by Type I Interferons and Interferon Regulatory Factor 1
- (2012) Xiangzhi Meng et al. JOURNAL OF VIROLOGY
- MVA–5T4-induced immune responses are an early marker of efficacy in renal cancer patients
- (2011) Richard Harrop et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
- (2011) M. Mohebtash et al. CLINICAL CANCER RESEARCH
- Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope
- (2011) Nermin Raafat et al. INTERNATIONAL JOURNAL OF CANCER
- Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
- (2011) Elisabeth Quoix et al. LANCET ONCOLOGY
- The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
- (2011) Kelley A Parato et al. MOLECULAR THERAPY
- Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
- (2011) Caroline J. Breitbach et al. NATURE
- Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2010) R. J. Amato et al. CLINICAL CANCER RESEARCH
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Vaccinia virus B5 protein affects the glycosylation, localization and stability of the A34 protein
- (2010) A. Breiman et al. JOURNAL OF GENERAL VIROLOGY
- A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer
- (2010) Rodryg Ramlau et al. Journal of Thoracic Oncology
- The Vaccinia Virus Complement Control Protein Modulates Adaptive Immune Responses during Infection
- (2010) N. M. Girgis et al. JOURNAL OF VIROLOGY
- Herpesviruses and Chromosomal Integration
- (2010) G. Morissette et al. JOURNAL OF VIROLOGY
- Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors
- (2010) Heather MacTavish et al. PLoS One
- Repulsion of Superinfecting Virions: A Mechanism for Rapid Virus Spread
- (2010) V. Doceul et al. SCIENCE
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
- (2009) James L. Gulley et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Host Lymphodepletion Enhances the Therapeutic Activity of an Oncolytic Vaccinia Virus Expressing 4-1BB Ligand
- (2009) H. S. Kim et al. CANCER RESEARCH
- Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α)
- (2009) Robert J. Amato et al. JOURNAL OF IMMUNOTHERAPY
- Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
- (2009) Howard L Kaufman et al. Journal of Translational Medicine
- Vaccinia Virus K1L and C7L Inhibit Antiviral Activities Induced by Type I Interferons
- (2009) X. Meng et al. JOURNAL OF VIROLOGY
- Intranodal Immunization With a Vaccinia Virus Encoding Multiple Antigenic Epitopes and Costimulatory Molecules in Metastatic Melanoma
- (2009) Michel Adamina et al. MOLECULAR THERAPY
- Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice
- (2008) Y Kulu et al. CANCER GENE THERAPY
- Enhancing Poxvirus Oncolytic Effects through Increased Spread and Immune Evasion
- (2008) D. H. Kirn et al. CANCER RESEARCH
- Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma
- (2008) J. L. Gulley et al. CLINICAL CANCER RESEARCH
- Immunogenic cancer cell death: a key-lock paradigm
- (2008) Antoine Tesniere et al. CURRENT OPINION IN IMMUNOLOGY
- The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma
- (2008) Ta-Chiang Liu et al. MOLECULAR THERAPY
- Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis
- (2008) T. L.-A. Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Vaccinia virus morphogenesis and dissemination
- (2008) Kim L. Roberts et al. TRENDS IN MICROBIOLOGY
- Vaccinia Virus E3 Protein Prevents the Antiviral Action of ISG15
- (2008) Susana Guerra et al. PLoS Pathogens
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started